Clinical trial
A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
NCT06609889 is registered in ClinicalTrials.gov with Berge Minassian as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
- Lead sponsor
- Berge Minassian
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- December 3, 2024
- Completion date
- October 31, 2028
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.